



NCL RESEARCH & FINANCIAL SERVICES LTD.

CIN no.: L65921MH1985PLC284739

Registered Office : 3rd Floor, Bhagyodaya Building, 79 Nagindas Master Road, Fort, Mumbai - 400023, Maharashtra
Tel/fax: 022-22703249 E-mail : ncl.research@gmail.com Website :- www.nclfin.com

15-09-2020

To
The Deputy Manager
Department of Corporate Services
BSE Limited
P.J. towers, Dalal Street, Fort,
Mumbai-400001

Ref.:- Scrip Code BSE-530557

Sub.:- Submission of Q-I Results along with Limited Review Report by Statutory Auditors.

Respected Sir or Madam,

With reference to the above and in compliance with Regulation 33(3) of SEBI LODR Regulations, 2015, we are enclosing herewith this letter, Un-Audited Financial Results (Standalone) for the 1st quarter ended on June 30, 2020 (Q-I) for the Financial Year ended on 31st March 2021 together with "Limited Review Report" by Statutory Auditors.

The meeting was commenced at **16:30 Hrs.** and concluded at **17:45 Hrs.**

Kindly take the same on your record & oblige.

This is for the information of Members

Thanking You

Your Faithfully

For **NCL Research & Financial Services Limited**

Goutam Bose
Managing Director
DIN 02504803

NCL RESEARCH & FINANCIAL SERVICES LIMITED

Reg. Office: 79, Bhagyodaya Building, 3rd Floor, Nagindas Master Road, Fort, Mumbai, Maharashtra-400023

CIN: L65921MH1985PLC284739; Email Id: ncl.research@gmail.com; Website: www.nclfin.com

Statement of UnAudited Financial Results for the Quarter Ended 30 June 2020

Rs. In Lakhs)

Sr. No.	Particulars	Quarter ended			Year Ended
		30-Jun-20	31-Mar-20	30-Jun-19	31-Mar-20
		Unaudited	Audited	Unaudited	Audited
A	Income				
1	Revenue from Operations				
	(i) Interest Income	48.589	24.569	110.628	214.136
	(ii) Dividend Income	-	-	-	-
	(iii) Rental Income	0.300	1.200	-	1.200
	(iv) Fees and commission Income	-	-	-	-
	(v) Net gain on fair value changes	-	-	-	-
	(vi) Net gain on derecognition of financial instruments under amortised cost category	-	-	-	-
	(vii) Sale of goods	-	1.461	-	27.837
	(viii) Sale of services	-	-	-	-
2	Other Revenue from Operations	-	-	-	-
3	Total Revenue from Operations	48.889	27.230	110.628	243.172
4	Other Income				
	(i) Other Interest	-	1.300	-	1.300
	Total Other Income	-	1.300	-	1.300
	TOTAL INCOME (3+4)	48.889	28.530	110.628	244.472
B	Expenses				
a	Finance Costs	-	-	-	-
b	Fees and commission expense	-	-	-	-
c	Net loss on fair value changes	-	-	-	-
d	Net loss on derecognition of financial instruments under amortised cost category	-	-	-	-
e	Impairment on financial instruments	-	-	-	-
f	Cost of materials consumed	-	-	-	-
g	Purchases of Stock-in-trade	0.913	-	-	118.828
h	Changes in Inventories of stock-in-trade	1.479	-3.855	2.531	34.251
i	Employee benefit expense	12.009	11.539	13.145	51.630
j	Depreciation, depletion and amortisation expense	-	-	-	-
k	Other Expenses				
	i Professional & Legal Fees, Charges and Expenses	-	2.072	0.250	8.372
	ii Stock Exchange & Other Regulatory Expenses	1.328	1.335	1.394	5.511
	iii Travelling & Conveyance Expenses	1.389	1.250	1.350	5.300
	iv Others	4.265	4.932	5.917	18.457
	TOTAL EXPENSES	21.383	17.273	24.587	242.349
C	TOTAL PROFIT BEFORE EXCEPTIONAL ITEMS AND TAX	27.506	11.257	86.041	2.124
	Exceptional items	-	-	-	-
D	TOTAL PROFIT BEFORE TAX	27.506	11.257	86.041	2.124
	Tax expense				
	Current tax	7.15	-0.545	22.371	0.561
	Deferred tax	-	-	-	0.013
E	Total tax expenses	7.152	-0.545	22.371	0.574
F	NET PROFIT (LOSS) FOR THE PERIOD FROM OPERATION	20.354	11.802	63.670	1.550
	Other comprehensive income net of taxes				
	Fair value changes on instruments carried at FVTOCI	-	-	-	-
	Tax effect on above items	-	-	-	-
G	TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	20.354	11.802	63.670	1.550
H	Details of equity share capital				
	Paid-up equity share capital	2,908.500	2,908.500	2,908.500	2,908.500
	Face value of equity share capital	2.000	2.000	2.000	2.000
I	Reserves excluding revaluation reserve	-	-	-	3,278.627
J	Earnings per share				
	Basic earnings per share from continuing operations	0.014	0.008	0.044	0.001
	Diluted earnings per share from continuing operations	0.014	0.008	0.044	0.001

Figures for the quarters ended 31 March 2020 as reported in these financial results, are the balancing figures between the published year to date figures up to the end of the third quarter and nine months ended of the respective period.

Notes:

- The standalone audited financial statements are prepared in accordance with the Indian Accounting Standards ("Ind-AS") as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 as amended and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015.
- The Financial Results of NCL RESEARCH & FINANCIAL SERVICES LIMITED ('the Company') for the period ended June 30, 2020 have been reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors in their meeting held on September 15, 2020 and have been subjected to Limited Review by the Statutory Auditors of the Company.
- As per Indian Accounting Standard (IndAS) 108 "Operating Segment", the Company's business falls within a single business segment viz. "Finance & Investments" and thus Segmental Report for the Quarter is not applicable to the Company.
- Figures for previous quarter/year have been re-stated/re-classified wherever necessary.
- The Company has considered the possible effects that may result from the pandemic relating to COVID 19 on the financial results of the Company. While evaluating the impact, the Company has considered possible future uncertainties in the economic conditions because of the pandemic. However, given the limited operations of the Company during the quarter ended June 30, 2020, there has been no material impact on the financial position/ results of the Company. The Company is continuously evaluating the impact of the pandemic and will undertake necessary disclosures, as may be required.

Date : 15-Sep-20
Place : Mumbai

For NCL Research & Financial Services Limited
Sd/-

 

Gautam Bose
Managing Director

¹ DBS & ASSOCIATES

Chartered Accountants

Independent Auditor's Review report on Interim Financial Results NCL RESEARCH & FINANCIAL SERVICES LIMITED Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Quarter ended 30th June, 2020.

**To,
The Board of Directors,
NCL RESEARCH & FINANCIAL SERVICES LIMITED,**

1. We have reviewed the accompanying statement of **un-audited** financial results of **NCL RESEARCH & FINANCIAL SERVICES LIMITED**. ("The Company") for the Quarter ended 30th June 2020 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognitions and measurement principal laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (IND AS-34), prescribed under section 133 of the Companies Act 2013 read with relevant rules issued there under and other accounting principal generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 *Review of Interim Financial Information performed by the Independent Auditors of the entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audited accordingly; we do not express an audit opinion.

Office Add.: 202, 93 of Poonam Complex, above HDFC Bank, Shañti Park, Mira Road East, Thane – 401 107.

Mobile No.: +91-9769794999, 9167653615

² DBS & ASSOCIATES Chartered Accountants

3. Based on our review conducted as above , nothing has come to our attention **except as mentioned in para 4** that causes us to believe that the accompanying statement, prepared in accordance with recognitions and measurement principles laid down in applicable Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act 2013, read with relevant rules issued there under and other recognized accounting practice and policies, has not disclose the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, including the manner in which it is to be disclosed, or that it contains any material misstatement.
4. Note on inventory of the un-audited financial statement, valuation of the quoted share named ARIHANT MULTI COMMERCIAL LIMITED (formally known as LIFELINE DRUGS & PHARMA LTD. Amounting Rs. 51.07 Lac (shown 38000 shares@134.40) are subject to the valuation by independent valuer as the shares were not traded on stock exchange since long time and the said company has not filed his latest financial to stock exchange since 2018. As per management representation and explanation, they are under process to carrying out fair valuation of these shares.

For **DBS & Associates**
Chartered Accountants
Firm Reg. No.: 081627N

Place: Mumbai

Dated: 15.09.2020



CA Roxy Teniwal
Partner
M No.: 141538
UDIN: 20141538AAAAAP2259

Office Add.: 202, 93 of Poonam Complex, above HDFC Bank, Shaanti Park, Mira Road East, Thane – 401 107.

Mobile No.: +91-9769794999, 9167653615